1. AHRO : Austin Health Research Online

Eliza A Hawkes

View Statistics Email Alert RSS Feed
 Claim profile

Profile

Loading... 2 0 20 0 false
Credit Name
Eliza A Hawkes
Full Name
Hawkes, Eliza A
 
Department
 
ORCID
Loading... 3 0 20 0 false

Publications

Results 61-75 of 75 (Search time: 0.007 seconds).

Publication YearTitleAuthor(s)
612018An abscopal effect may augment PD-1 inhibition in refractory classical Hodgkin lymphoma.Wight, Joel C ; Hawkes, Eliza A ; Berlangieri, Salvatore U ; Khor, Richard ; Grigg, Andrew P 
622018Routine blood investigations have limited utility in surveillance of aggressive lymphoma in asymptomatic patients in complete remission.Hawkes, Eliza A ; Loh, Zoe ; Estacio, Ortis; Chong, Geoffrey ; Ha, Francis J; Gilbertson, Michael; Grigg, Andrew P 
6320-Dec-2017Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support.Opat, Stephen; Hawkes, Eliza A 
641-Oct-2017Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial.Gleeson, M; Counsell, Nicholas; Cunningham, D; Chadwick, N; Lawrie, A; Hawkes, Eliza A ; McMillan, A; Ardeshna, K M; Jack, A; Smith, P; Mouncey, P; Pocock, C; Radford, J A; Davies, J; Turner, D; Kruger, A; Johnson, P ; Gambell, J; Linch, D
65Aug-2017Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003-2013.Gleeson, Mary; Hawkes, Eliza A ; Peckitt, Clare; Wotherspoon, Andrew; Attygalle, Ayoma; Sharma, Bhupinder; Du, Yong; Ethell, Mark; Potter, Mike; Dearden, Claire; Horwich, Alan; Chau, Ian; Cunningham, David
661-Jul-2017Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.Kühnl, A; Cunningham, D; Counsell, Nicholas; Hawkes, Eliza A ; Qian, W; Smith, P; Chadwick, N; Lawrie, A; Mouncey, P; Jack, A; Pocock, C; Ardeshna, Kirit M; Radford, J; McMillan, A; Davies, J; Turner, D; Kruger, A; Johnson, P W; Gambell, J; Rosenwald, A; Ott, G; Horn, H; Ziepert, M; Pfreundschuh, M; Linch, D
7Jun-2017Efficacy and toxicity of PACEBOM chemotherapy in relapsed/refractory aggressive lymphoma in the rituximab eraTamjid, Babak ; Mckendrick, Joseph; Schwarer, Anthony P ; Doig, Rowan; James, Philip; Hosking, Patrick; Hawkes, Eliza A 
8Feb-2017Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patientMurphy, C; Hawkes, E ; Chionh, Fiona; Chong, Geoff
920-Jan-2017Is Upfront Escalated BEACOPP for Advanced Hodgkin Lymphoma Becoming a Distant Memory?Hawkes, Eliza A ; Chong, Geoffrey ; Grigg, Andrew P 
10Jan-2017Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximabKu, Matthew; Chong, Geoff; Hawkes, Eliza A 
111-Aug-2016Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialGleeson, Mary; Hawkes, Eliza A ; Cunningham, David; Chadwick, Nick; Counsell, Nicholas; Lawrie, Anthony; Jack, Andrew; Smith, Paul; Mouncey, Paul; Pocock, Christopher; Ardeshna, Kirit M; Radford, John; McMillan, Andrew; Davies, John; Turner, Deborah; Kruger, Anton; Johnson, Peter WM; Gambell, Joanna; Linch, David
12Apr-2016Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern eraJalali, Azim; Ha, Francis J; Chong, Geoff; Grigg, Andrew P ; Mckendrick, Joe; Schwarer, Anthony P ; Doig, Rowan; Hamid, Anis; Hawkes, Eliza A 
131-May-2015Programmed cell death-1 inhibition in lymphoma.Hawkes, Eliza A ; Grigg, Andrew P ; Chong, Geoffrey 
1417-Feb-2015Diagnostic medical radiation exposure in surveillance of aggressive lymphoma: clinical trial design should reflect clinical practice.Hawkes, Eliza A ; Chong, Geoffrey ; Grigg, Andrew P 
151-Jul-2014ASPECCT: panitumumab versus cetuximab for colorectal cancer.Hawkes, Eliza A ; Wong, Rachel